Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2019

29.06.2017 | Case Report

Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer

verfasst von: Nikolaos Miaris, Joseph Sgouros, Margarita Gerolympou, Basilios Spyropoulos, Dionysios Drakopoulos, Stefania Gkoura, Helen Res, Epaminondas Samantas

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Posterior reversible encephalopathy syndrome (PRES) is an urgent neurologic condition that is associated with white and gray matter vasogenic edema primarily in parietal and occipital lobes [1]. Clinical features usually involve headache, altered mental status, seizures, and visual disturbances [1]. Although PRES is generally a rare reversible condition, it is increasingly reported in the literature, especially in the setting of cancer patients treated with chemotherapy and antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) pathway. …
Literatur
2.
Zurück zum Zitat Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. doi:10.1200/JCO.2012.42.8201.CrossRef Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. doi:10.​1200/​JCO.​2012.​42.​8201.CrossRef
5.
Zurück zum Zitat Kamiya-Matsuoka C, Paker AM, Chi L, et al. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neuro-Oncol. 2016;128(1):75–84. doi:10.1007/s11060-016-2078-0.CrossRef Kamiya-Matsuoka C, Paker AM, Chi L, et al. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neuro-Oncol. 2016;128(1):75–84. doi:10.​1007/​s11060-016-2078-0.CrossRef
7.
Zurück zum Zitat Miaris N, Maltezou M, Papaxoinis G, et al. Posterior reversible encephalopathy syndrome with concurrent nephrotic syndrome in a patient treated with pazopanib for metastatic renal cell carcinoma: case report and review of the literature. Clin Genitourin Cancer. 2017; doi:10.1016/j.clgc.2016.08.005. Miaris N, Maltezou M, Papaxoinis G, et al. Posterior reversible encephalopathy syndrome with concurrent nephrotic syndrome in a patient treated with pazopanib for metastatic renal cell carcinoma: case report and review of the literature. Clin Genitourin Cancer. 2017; doi:10.​1016/​j.​clgc.​2016.​08.​005.
10.
Zurück zum Zitat How J, Blattner M, Fowler S, et al. Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature. Neurologist 2016;21(6):112–7. doi:10.1097/NRL.0000000000000105. How J, Blattner M, Fowler S, et al. Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature. Neurologist 2016;21(6):112–7. doi:10.​1097/​NRL.​0000000000000105​.
11.
Zurück zum Zitat Myint ZW, Sen JM, Watts NL, et al. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature Review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Clin Colorectal Cancer. 2017;13(2):127–30. doi:10.1016/j.clcc.2013.12.003.CrossRef Myint ZW, Sen JM, Watts NL, et al. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature Review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Clin Colorectal Cancer. 2017;13(2):127–30. doi:10.​1016/​j.​clcc.​2013.​12.​003.CrossRef
13.
Zurück zum Zitat Dedić Plavetić N, Rakušić Z, Ozretić D, et al. Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen. World J Surg Oncol. 2014;12(1):264. doi:10.1186/1477-7819-12-264.CrossRefPubMedPubMedCentral Dedić Plavetić N, Rakušić Z, Ozretić D, et al. Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen. World J Surg Oncol. 2014;12(1):264. doi:10.​1186/​1477-7819-12-264.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Chen H, Modiano MR, Neal JW, et al. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2014;110(3):602–8. doi:10.1038/bjc.2013.735.CrossRefPubMed Chen H, Modiano MR, Neal JW, et al. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2014;110(3):602–8. doi:10.​1038/​bjc.​2013.​735.CrossRefPubMed
19.
Metadaten
Titel
Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer
verfasst von
Nikolaos Miaris
Joseph Sgouros
Margarita Gerolympou
Basilios Spyropoulos
Dionysios Drakopoulos
Stefania Gkoura
Helen Res
Epaminondas Samantas
Publikationsdatum
29.06.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2019
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-017-9986-x

Weitere Artikel der Ausgabe 1/2019

Journal of Gastrointestinal Cancer 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.